research reports and media, page-1267

Nahh, I came across this the other day thanks to a poster on here...

Here was my response a number of days ago:

Very interesting..but think it's only a headline, unfortunately for them....

1) They are at the very start of their journey, mouse model just completed, human trials will take 5 years plus

2) Reports of nasties, see this:

" A review of the literature, however, indicates that paroxetine has serious side and adverse drug effects ranging from congenital birth defects and heart abnormalities to breast and other possible cancers. It also may, along with other SSRIs and SNRIs, increase suicidality, aggression and akathisia in pediatric patients with incidence outcomes which initially may have been significantly underestimated in clinical trials. Women with a family history of breast cancer should only be initiated or maintained on paroxetine therapy when effective treatment cannot be rendered by other SSRIs, another class of antidepressants or anxiolytics,"


...as well as concluding by stating:

"Overall, however, the problems and risks associated with paroxetine appear to possibly make it the least safe of all SSRIs and SNRIs and, if not for the low therapeutic indices of TCAs and MAOIs, possible cardiotoxicity and increased risk of serotonin syndrome, possibly the least safe of all antidepressants. These conclusions should lead practitioners to be much more cautious than with other antidepressants in recommending, initiating and continuing treatment with paroxetine, especially in females."


The above is from a peer reviewed article:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044489/

Onwards and upwards for us

- Mozz